Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence.

ABSTRACT: The diverse clinical outcomes of prostate cancer have led to the development of gene signature assays predicting disease progression. Improved prostate cancer progression biomarkers are needed as current RNA biomarker tests have varying success for intermediate prostate cancer. Interest grows in universal gene signatures for invasive carcinoma progression. Early breast and prostate cancers share characteristics, including hormone dependence and BRCA1/2 mutations. Given the similarities in the pathobiology of breast and prostate cancer, we utilized the NanoString BC360 panel, comprising the validated PAM50 classifier and pathway-specific signatures associated with general tumor progression as well as breast cancer-specific classifiers. This retrospective cohort of primary prostate cancers (

SUBMITTER: Lautert-Dutra W 

PROVIDER: S-EPMC10641020 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature